Biotech

We said it yesterday, and we'll say it again - biotech is ht right now. The JP Morgan conference is drawing to a close, and with it, we have seen a flurry of deals done and data drop. Here's the latest news form the institutional side of things, involving...

Xenetic Biosciences, Inc. (NASDAQ: XBIO), a clinical-stage biopharmaceutical company focused on the discovery, research & development of next-generation biologic drugs, announced that it received a $3 million milestone payment from Shire plc (LSE: SHP, NASDAQ:SHPG) related to Shire’s advancing the Phase 1/2a clinical study for the PSA-Recombinant SHP656 or Factor VIII...

The medical device space has drawn a lot of attention as late. It's become one of those sectors - just as with the more chemical oriented biotech/healthcare space - that is prone to real swings and roundabouts as data hits from the clinical trial process. These data hits serve...

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) shares popped up 72.85% to $23.75 on Monday then pulled back 0.04% to $23.74 in after-hours trading. Share prices have been trading in a 52-week range of $4.37 to $23.81 so it's already at the resistance. The company has a market cap of $4.73 billion...

Applied DNA Sciences Inc (NASDAQ:APDN) shares dipped 2.63% on Friday to $1.85 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $1.73 to $3.74. The company has a market cap of $47.47 million at 26.35 million shares outstanding. Applied DNA Sciences Inc is...